Investors — NMD Pharma
Company Presentation
NMD Pharma - Inkef capital
NMD Pharma A/S | LinkedIn
NMD Pharma A/S | LinkedIn
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
Roel Bulthuis - Director at NMD Pharma | The Org
NMD Pharma - Capnova
NMD Pharma treats first patient with the firm's most promising drug candidate
Nete Huus's email & phone | NMD Pharma ApS's Senior Scientist email
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma raises $47M in series A investment round from INKEF and existing investors, to advance treatments of neuromuscular disorders | Nordic 9
NMD Pharma, finalist i Life Sciences kategorien - EY Danmark
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis | MENAFN.COM
Big deal: NMD flexes series A muscles - Global University Venturing
NMD Pharma | The Org
Management — NMD Pharma
NMD Pharma, finalist i Life Sciences kategorien - EY Danmark
NMD | LinkedIn
NMD Pharma Information | NMD Pharma Profile
NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
Prominent Canadian researcher in Denmark: Why I left a top job in California
